CLADIN- CLADribine and INnate immune response in multiple sclerosis - A phase IV prospective study - Articles - Dermatology · Immunology · Rheumatology

Allergic Diseases

Subclinical immune responses to nickel in sensitized individuals-a dose-response study

Contact Dermatitis

Wennervaldt M, Vaher H, Ahlström MG, Bischofberger N, Menné T, Thyssen JP, Johansen JD, Bonefeld CM

doi: 10.1111/cod.14549

Further Publications Immunology

Association of Cutaneous Immune-related Adverse Events with Overall Survival and Progression-free Survival in Oncology Patients Receiving Immune Checkpoint Inhibitors: A Prospective Study of 189 Patients in a Spanish Tertiary Care Hospital

Acta Derm Venereol

Juan-Carpena G, Martínez Banaclocha N, Palazón Cabanes JC, Niveiro-de Jaime M, Betlloch Mas I, Blanes-Martínez M

doi: 10.2340/actadv.v105.42023

Rheumatoid Arthritis

Dose-Response Associations Between Diet and Risk of Rheumatoid Arthritis: A Meta-Analysis of Prospective Cohort Studies

Nutrients

Dong Y, Greenwood DC, Webster J, Uzokwe C, Tao J, Hardie LJ, Cade JE

doi: 10.3390/nu16234050

Systemic Sclerosis

Racial variability in immune responses only partially explains differential systemic sclerosis disease severity

Ann Rheum Dis

Kuchinad KE, Kim JS, Woods A, Leatherman G, Gutierrez-Alamillo L, Mayes MD, Domsic R, Ramos PS, Silver RM, Varga J, Saketkoo LA, Kafaja S, Shanmugan VK, Gordon J, Chung L, Bernstein EJ, Gourh P, Boin F, Kastner DL, Zeger SL, Casciola-Rosen L, Wigley FM, Shah AA

doi: 10.1136/ard-2023-225458

Further Publications Immunology

COVID-19 Vaccine Side Effects and Long-Term Neutralizing Antibody Response : A Prospective Cohort Study

Ann Intern Med

Dutcher EG, Epel ES, Mason AE, Hecht FM, Robinson JE, Drury SS, Prather AA

doi: 10.7326/M23-2956

Alopecia Areata

Efficacy and safety of the oral JAK3/TEC family kinase inhibitor ritlecitinib over 24 months: integrated analysis of the ALLEGRO phase 2b/3 and long-term phase 3 clinical studies in alopecia areata

Br J Dermatol

Piliang M, Soung J, King B, Shapiro J, Rudnicka L, Farrant P, Magnolo N, Piraccini BM, Luo X, Wolk R, Woodworth D, Schaefer G, Lejeune A

doi: 10.1093/bjd/ljae365

Psoriatic Arthritis

Efficacy and safety of tofacitinib in an open-label, long-term extension study in patients with psoriatic arthritis who received adalimumab or tofacitinib in a Phase 3 randomized controlled study: a post hoc analysis

Arthritis Res Ther

Gladman DD, Nash P, Mease PJ, FitzGerald O, Duench S, Cadatal MJ, Masri KR

doi: 10.1186/s13075-024-03442-2

Psoriatic Arthritis

Sustained response to guselkumab regardless of baseline characteristics in patients with active psoriatic arthritis and inadequate response to TNF inhibitors: results from the phase 3b COSMOS clinical trial

RMD Open

McInnes IB, Sewerin P, Sharaf M, Efficace M, Lavie F, Zimmermann M, Coates LC

doi: 10.1136/rmdopen-2024-004494

Further Publications Immunology

Effectiveness of a symptom-clinic intervention delivered by general practitioners with an extended role for people with multiple and persistent physical symptoms in England: the Multiple Symptoms Study 3 pragmatic, multicentre, parallel-group, individually randomised controlled trial

Lancet

Burton C, Mooney C, Sutton L, White D, Dawson J, Neilson AR, Rowlands G, Thomas S, Horspool M, Fryer K, Greco M, Sanders T, Thomas RE, Cooper C, Turton E, Waheed W, Woodward J, Mallender E, Deary V

doi: 10.1016/S0140-6736(24)00700-1

Related content

Subclinical immune responses to nickel in sensitized individuals-a dose-response study

Association of Cutaneous Immune-related Adverse Events with Overall Survival and Progression-free Survival in Oncology Patients Receiving Immune Checkpoint Inhibitors: A Prospective Study of 189 Patients in a Spanish Tertiary Care Hospital

Dose-Response Associations Between Diet and Risk of Rheumatoid Arthritis: A Meta-Analysis of Prospective Cohort Studies

Racial variability in immune responses only partially explains differential systemic sclerosis disease severity

COVID-19 Vaccine Side Effects and Long-Term Neutralizing Antibody Response : A Prospective Cohort Study

Efficacy and safety of the oral JAK3/TEC family kinase inhibitor ritlecitinib over 24 months: integrated analysis of the ALLEGRO phase 2b/3 and long-term phase 3 clinical studies in alopecia areata

Efficacy and safety of tofacitinib in an open-label, long-term extension study in patients with psoriatic arthritis who received adalimumab or tofacitinib in a Phase 3 randomized controlled study: a post hoc analysis

Sustained response to guselkumab regardless of baseline characteristics in patients with active psoriatic arthritis and inadequate response to TNF inhibitors: results from the phase 3b COSMOS clinical trial

Effectiveness of a symptom-clinic intervention delivered by general practitioners with an extended role for people with multiple and persistent physical symptoms in England: the Multiple Symptoms Study 3 pragmatic, multicentre, parallel-group, individually randomised controlled trial